Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam extended infusions in infants and children
NCT02466438Phase 1Unknown
- Sponsor
- Centre Hospitalier Universitaire Sainte-Justine
- Start
- Jan 2016
- Primary completion
- Dec 2018
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of piperacillin + tazobactam in Infection, sponsored by Centre Hospitalier Universitaire Sainte-Justine. Primary endpoints: Clearance at 14 days and Time above MIC at 14 days. Status: unknown.
02
Drugs
piperacillin + tazobactam
03
Conditions
Infection
Beyond the preview
Go deeper on NCT02466438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466438.